A BRAF mutation test looks for changes in the BRAF gene, which controls part of the MAPK signaling pathway that tells cells when to grow. The most important result is often BRAF V600E, but laboratories may also detect V600K, other V600 substitutions, and non-V600 alterations. Most BRAF mutations found in a tumor are acquired, or somatic, rather than inherited.
The meaning changes sharply by cancer type. In melanoma, lung cancer, and some thyroid cancers, a BRAF V600 mutation can identify targeted treatment with a BRAF inhibitor plus a MEK inhibitor. In metastatic colorectal cancer, BRAF V600E treatment also requires blocking EGFR because colon tumors can reactivate the pathway. In a colorectal tumor with loss of MLH1 and PMS2, BRAF V600E supports a sporadic cause but does not replace complete Lynch syndrome evaluation. A negative result can reflect true wild-type BRAF, low tumor content, limited assay coverage, or insufficient tumor DNA.
- BRAF V600E is the most common actionable BRAF alteration, but non-V600 variants can have different biology and treatment options.
- A positive result is interpreted by cancer type; the same mutation does not lead to the same treatment in every tumor.
- Tumor BRAF mutations are usually somatic and do not automatically imply inherited cancer risk.
- A negative result may need confirmation with broader sequencing or a new specimen when tumor content is low.
- BRAF protein immunostaining, PCR, sequencing, and liquid biopsy have different strengths and limits.
Table of Contents
- What BRAF Mutations Do
- When BRAF Testing Is Used
- How the Test Is Performed
- How to Read BRAF Results
- BRAF in Melanoma
- BRAF in Colorectal Cancer
- BRAF in Thyroid and Lung Cancer
- Limitations, Treatment Resistance, and Next Steps
What BRAF Mutations Do
BRAF encodes a kinase in the RAS–RAF–MEK–ERK pathway. Normal growth signals activate this pathway briefly. An activating BRAF mutation can keep the pathway switched on, allowing tumor cells to divide without the usual external signal. BRAF is therefore a driver gene in several cancers.
BRAF alterations are often grouped by how they signal:
- Class 1 mutations are usually V600 substitutions, especially V600E. They signal as active BRAF monomers and generally have high kinase activity.
- Class 2 mutations activate signaling as dimers and do not require upstream RAS activity. This group includes some non-V600 substitutions, fusions, and in-frame deletions.
- Class 3 mutations have low or impaired BRAF kinase activity but increase pathway signaling through RAS and CRAF. Their effect depends on upstream activation.
This classification helps explain why a drug effective against V600E may not work against another BRAF variant. Some BRAF inhibitors can paradoxically activate MAPK signaling in a BRAF-wild-type or RAS-active tumor, which is why treatment requires a validated biomarker and cancer-specific evidence.
The notation BRAF p.Val600Glu, BRAF V600E, and c.1799T>A describe the same common protein and DNA change at different levels. A report may list an allele fraction, such as 18%. That percentage estimates the proportion of analyzed DNA molecules carrying the variant; it is not the percentage of the body affected by cancer and is influenced by tumor purity, copy number, and normal-cell contamination.
Most tumor BRAF variants are somatic. Rare inherited pathogenic BRAF variants cause developmental conditions in the RASopathy spectrum, such as cardiofaciocutaneous syndrome, rather than the usual hereditary adult cancer syndromes. A BRAF V600E result in a melanoma or colon tumor does not ordinarily justify testing relatives.
BRAF status is one component of somatic tumor testing. Other genes, tumor type, stage, prior therapy, and overall health remain essential. A driver mutation can be actionable without being the only cause of the cancer.
When BRAF Testing Is Used
BRAF testing is ordered when the result can guide therapy, refine diagnosis, estimate prognosis, or help evaluate hereditary risk through a tumor-screening pathway. The recommended patient group differs by disease and continues to expand as treatments change.
Common uses include:
- Unresectable or metastatic melanoma
- High-risk or resected melanoma when adjuvant targeted therapy is being considered
- Metastatic colorectal cancer
- Colorectal cancer with deficient mismatch repair caused by MLH1/PMS2 loss
- Advanced non-small cell lung cancer, especially nonsquamous disease
- Anaplastic thyroid cancer and selected advanced differentiated thyroid cancers
- Hairy cell leukemia and selected histiocytic disorders
- Tumors of uncertain origin in which a characteristic BRAF alteration may aid classification
- Broad genomic profiling of rare or treatment-resistant cancers
In melanoma, testing should identify V600E and other clinically relevant V600 substitutions, particularly V600K. A test limited to V600E can miss patients who may benefit from an approved BRAF/MEK combination. Tissue from the primary melanoma or a metastasis may be used, although a recent metastatic specimen can better represent current disease.
In metastatic colorectal cancer, BRAF V600E provides prognostic information and selects a distinct targeted strategy. Testing is commonly included in a panel with KRAS, NRAS, mismatch repair or microsatellite instability, and other relevant markers. The result should be available early enough to guide the treatment sequence.
In colorectal tumors showing loss of MLH1 and PMS2 by immunohistochemistry, BRAF V600E strongly favors sporadic MLH1 promoter methylation rather than Lynch syndrome. Many laboratories test BRAF, MLH1 promoter methylation, or both. The absence of BRAF V600E does not prove Lynch syndrome; germline evaluation depends on methylation results, age, personal history, and family history.
In advanced nonsquamous non-small cell lung cancer, broad molecular profiling usually includes BRAF along with EGFR, ALK, ROS1, KRAS, MET, RET, NTRK, ERBB2, and others. A narrow V600 assay may be adequate for an approved V600E therapy question but will not characterize non-V600 variants or alternative drivers.
Thyroid testing depends on histology and clinical setting. Molecular analysis of an indeterminate thyroid nodule may help estimate malignancy risk, while testing an anaplastic thyroid cancer urgently for BRAF V600E can open a rapidly acting targeted option. BRAF V600E in papillary thyroid carcinoma is common, but it should not by itself dictate the extent of surgery or radioactive iodine treatment.
How the Test Is Performed
Tumor tissue testing
Most testing uses formalin-fixed, paraffin-embedded tissue from a biopsy or surgery. A pathologist marks the tumor-rich area and estimates tumor percentage. The laboratory may scrape or microdissect that area to reduce normal-cell dilution. Small biopsies, cytology cell blocks, and fine-needle aspiration material can work when enough tumor DNA is present.
PCR-based assays are fast and sensitive for selected hotspot mutations. Some detect V600E only; others cover several V600 variants. Their weakness is narrow coverage. A negative hotspot result cannot exclude a non-V600 BRAF mutation, fusion, or deletion.
Next-generation sequencing examines many genes and variant types at once. It may detect single-nucleotide changes, small insertions or deletions, copy-number changes, and selected fusions. RNA sequencing improves fusion detection. Coverage, analytic sensitivity, and structural-variant design vary by laboratory, so the report’s methods section matters.
Immunohistochemistry with a mutation-specific antibody can identify BRAF V600E protein in some tumor types. It is fast and preserves tissue, but staining quality and tumor-specific validation matter. Equivocal, weak, or clinically discordant staining often requires molecular confirmation.
Liquid biopsy
A blood-based test analyzes circulating tumor DNA within cell-free DNA. It can be useful when tissue is unavailable, biopsy is unsafe, or rapid broad profiling is needed. A positive BRAF result in the correct clinical context can be actionable. A negative blood result is less conclusive because some tumors shed little DNA, especially when disease volume is low or confined to the brain, lung, or peritoneum.
A circulating tumor DNA test can also detect alterations from clonal hematopoiesis, although BRAF V600E is less typical of that confounder than several blood-cancer genes. Tissue confirmation may be useful when the result is unexpected.
Specimen quality and turnaround
No fasting is needed for tissue molecular analysis. Preparation depends on the biopsy procedure. Blood testing requires a specialized collection tube and prompt processing according to the laboratory’s protocol. Tissue results often take several days to three weeks; focused PCR or immunohistochemistry may be faster.
Decalcified bone tissue, old blocks, necrotic samples, and very small biopsies can produce failure or false-negative results. If the sample has low tumor percentage, the report should state whether it met the assay’s validated minimum.
How to Read BRAF Results
A BRAF report should name the exact variant, specimen, method, tumor percentage, allele fraction when available, classification, and any therapy or trial associations. “BRAF positive” is incomplete because V600E, a class 2 fusion, and a class 3 missense variant have different implications.
| Result | Usual meaning | Important follow-up |
|---|---|---|
| BRAF V600E or another V600 mutation detected | An activating class 1 driver is present. | Match treatment to the cancer type and approved indication. |
| Non-V600 pathogenic BRAF variant | A class 2 or class 3 alteration may be driving MAPK signaling. | Confirm functional class and disease-specific evidence; a V600 regimen may not apply. |
| No BRAF mutation detected | No covered alteration was found above the detection limit. | Review coverage, tumor content, and whether broader or repeat testing is needed. |
| Variant of uncertain significance | The biological and clinical effect is not established. | Do not use it alone to select targeted therapy. |
| Insufficient or failed | The sample could not produce a reliable result. | Test another block, new biopsy, or plasma when appropriate. |
A pathogenic mutation can be both predictive and prognostic. Predictive means it may identify benefit from a treatment. Prognostic means it is associated with the disease’s natural course. These roles differ by cancer. For example, BRAF V600E in metastatic colorectal cancer is generally associated with aggressive biology, while its prognostic effect in papillary thyroid cancer is not strong enough to replace standard clinicopathologic risk factors.
A negative report should be read alongside the test menu. “BRAF V600E not detected” does not mean “no BRAF alteration.” Similarly, a DNA panel may miss a fusion if intronic regions or RNA are not covered. When the tumor type commonly has BRAF fusions, RNA testing may add value.
A tumor result does not establish whether the variant is inherited. If the allele fraction is near 50%, that can still be caused by a somatic heterozygous mutation in a tumor-rich sample. Germline confirmation uses blood, saliva, or another non-tumor sample and is usually considered only when the variant and clinical context suggest a hereditary condition.
BRAF in Melanoma
About 40% to 50% of cutaneous melanomas carry a BRAF mutation, most often V600E and then V600K. Rates differ by age, sun-damage pattern, and melanoma subtype. Acral and mucosal melanomas have lower BRAF V600 frequencies and may carry KIT, NRAS, or other drivers.
For unresectable or metastatic BRAF V600-mutant melanoma, approved BRAF and MEK inhibitor combinations can shrink tumors quickly. Common combinations include dabrafenib plus trametinib, encorafenib plus binimetinib, and vemurafenib plus cobimetinib, depending on jurisdiction and indication. Combining pathway levels improves response and reduces some toxicities compared with a BRAF inhibitor alone.
Immune checkpoint therapy is another major option. The choice and sequence depend on symptoms, tumor burden, brain metastases, need for rapid control, autoimmune disease, prior therapy, and patient preference. Targeted therapy often produces fast responses, while immunotherapy can produce durable control in some patients. A BRAF result creates an option; it does not automatically identify the best first treatment for every person.
Adjuvant dabrafenib plus trametinib can be considered after complete surgery for selected high-risk BRAF V600-mutant melanoma. The pathology stage, nodal involvement, recurrence risk, toxicity, and competing immunotherapy options guide the decision.
BRAF inhibitors can cause fever, rash, fatigue, joint symptoms, liver-test abnormalities, eye inflammation, heart effects, and secondary skin lesions. MEK inhibition can affect heart function and the retina. Prompt reporting of persistent fever, vision change, shortness of breath, or severe rash allows safer management.
A melanoma can become resistant through MAPK pathway reactivation, BRAF amplification or splice changes, NRAS or MEK alterations, and parallel survival pathways. A new biopsy or plasma profile at progression may identify a trial option, but resistance testing is not always required for routine next-line treatment.
BRAF in Colorectal Cancer
BRAF V600E occurs in roughly 8% to 12% of colorectal cancers. These tumors are often right-sided, occur more frequently in older adults and women, and may have mucinous features. Many arise through the serrated pathway and have MLH1 promoter methylation with microsatellite instability.
In metastatic colorectal cancer, BRAF V600E generally signals a poorer average prognosis than BRAF-wild-type disease, although individual outcomes vary and immunotherapy can be highly effective when the tumor is mismatch-repair deficient or microsatellite-instability high. Treatment selection therefore considers BRAF, RAS, MSI/MMR, HER2, tumor location, disease burden, and prior therapy together.
BRAF inhibition alone works poorly in colorectal cancer because EGFR signaling rapidly reactivates the MAPK pathway. Effective targeted regimens include an EGFR antibody with a BRAF inhibitor. As of 2026 in the United States, encorafenib with cetuximab and fluorouracil-based chemotherapy has traditional FDA approval for adults with metastatic BRAF V600E-mutant colorectal cancer; encorafenib plus cetuximab also has an established role after prior therapy. Local approvals and guidelines should be checked because indications can change.
Non-V600 BRAF colorectal cancers form a smaller, varied group. Class 3 tumors may be left-sided and have a different prognosis from V600E disease. They should not automatically receive a V600E regimen. Molecular tumor-board review or a clinical trial can help when evidence is limited.
For Lynch syndrome triage, BRAF V600E is relevant mainly when a colorectal tumor lacks MLH1 and PMS2. Its presence makes an inherited MLH1 pathogenic variant unlikely, but rare exceptions exist. In an early-onset patient or a family with strong Lynch-pattern cancers, genetics review may still be appropriate. BRAF testing has less value for this purpose when another mismatch-repair protein pattern is missing.
BRAF in Thyroid and Lung Cancer
BRAF V600E is found in a large proportion of papillary thyroid carcinomas and in many anaplastic thyroid cancers. In an indeterminate thyroid nodule, a positive result can raise the likelihood of papillary thyroid carcinoma, but the predictive value depends on the test platform and local cancer prevalence. The result should be combined with ultrasound, cytology, nodule size, lymph nodes, and patient preferences.
In papillary thyroid cancer, BRAF V600E is associated with some adverse features at the population level, but it is too common and insufficiently specific to determine prognosis alone. Age, tumor size, invasion, nodal and distant spread, histologic subtype, surgical findings, and response to initial therapy remain more informative. Molecular results may refine, rather than replace, established risk systems.
Anaplastic thyroid cancer can progress rapidly. Urgent BRAF V600E testing is important because dabrafenib plus trametinib can produce meaningful responses in mutation-positive disease and may make surgery possible in selected cases. Testing should not delay airway assessment or multidisciplinary care.
In advanced non-small cell lung cancer, BRAF mutations occur in a small percentage of tumors. About half are V600E, while the rest include class 2 and class 3 variants. Approved BRAF/MEK combinations for metastatic BRAF V600E-mutant NSCLC include dabrafenib plus trametinib and encorafenib plus binimetinib in the United States. Treatment choice considers prior therapy, brain disease, performance status, and toxicity.
Non-V600 lung-cancer variants do not have the same established targeted standard. Some class 3 tumors depend on upstream signaling and may coexist with other drivers. Broad DNA and RNA profiling helps determine whether BRAF is the main alteration and identifies clinical trials.
BRAF V600E also supports the diagnosis of classic hairy cell leukemia in the appropriate blood and marrow setting. Its absence should prompt evaluation for variant hairy cell leukemia and other splenic B-cell neoplasms rather than excluding a blood cancer solely from one assay.
Limitations, Treatment Resistance, and Next Steps
Every BRAF method trades breadth, speed, sensitivity, and tissue use. A rapid V600E immunostain may answer an urgent anaplastic thyroid cancer question but miss V600K. A broad DNA panel may detect many substitutions but miss an RNA fusion. Plasma can capture multiple metastatic sites but return false-negative when shedding is low.
Tumor heterogeneity can produce discordance between the primary cancer and a metastasis, although major drivers are often shared. A result from many years earlier may not capture resistance changes after several therapies. Retesting is most useful when it can open a new treatment or clarify an unexpected disease course.
Questions to ask include:
- What exact BRAF variant and functional class were found?
- Did the assay cover all V600 variants, non-V600 mutations, and fusions?
- Was the specimen adequate and tumor-rich?
- Is the result from tissue or plasma, and does a negative plasma test need tissue follow-up?
- Which treatment is supported for this specific cancer type and line of therapy?
- Are MSI/MMR, RAS, and other required biomarkers available?
- Does the result affect inherited-cancer evaluation, or is it clearly somatic?
- Is a clinical trial appropriate for a non-V600 alteration?
Do not use a BRAF inhibitor prescribed for one cancer as though it applies to another. Drug combinations, doses, companion testing, and evidence differ. Treatment should be supervised by an oncology team familiar with pathway-specific toxicities and interactions.
Urgent medical attention may be needed for severe treatment-related fever, dehydration, breathing difficulty, chest pain, sudden vision changes, confusion, or a widespread blistering rash. The mutation report itself is not an emergency, but aggressive diseases such as anaplastic thyroid cancer can require action within days.
A complete interpretation names the variant and cancer together: “BRAF V600E-mutant metastatic colorectal cancer” communicates far more than “BRAF positive.” That disease-specific wording is the bridge between a molecular result and a safe treatment plan.
When a second opinion is useful
Molecular review is especially helpful when the report lists a rare non-V600 variant, assigns conflicting classifications, or recommends a drug without clear evidence for that tumor type. A molecular pathologist can verify the sequence, transcript, allele fraction, and assay coverage. A multidisciplinary tumor board can then compare approved treatments, guideline-supported off-label options, and trials. When tissue is scarce, the team should decide whether confirmation is worth consuming the remaining block. Sometimes preserving material for a broader RNA panel or an essential immunostain has greater value than repeating the same narrow assay.
References
- BRAF Targeting Across Solid Tumors: Molecular Aspects and Clinical Implications 2025 (Review)
- Expert consensus on the diagnosis and treatment of solid tumors with BRAF mutations 2024 (Position Statement)
- BRAF V600E in thyroid cancer: navigating prognostic uncertainty and therapeutic opportunity 2025 (Review)
- BRAF V600E liquid biopsy-based detection in precision oncology: clinical applications and challenges 2025 (Review)
- FDA grants traditional approval to encorafenib for metastatic colorectal cancer with a BRAF V600E mutation 2026
- BRAFTOVI (encorafenib) prescribing information 2024
Disclaimer
This article is educational and does not replace tumor-specific interpretation by a pathologist, molecular laboratory, and oncology team. BRAF results must be matched to the exact variant, cancer type, stage, specimen quality, other biomarkers, current drug approvals, and the patient’s health. Do not start, stop, or combine targeted medicines without specialist direction.
